Brittany Cote

Articles

Breaking Down the Benefit of Neoadjuvant Nivolumab/Ipilimumab in Stage III Macroscopic Melanoma

August 12th 2020

Christian U. Blank, MD, PhD, discusses the promise of neoadjuvant ipilimumab/nivolumab and research efforts examining interferon-gamma signature and tumor mutational burden as potential predictors of response.

CDK4/6 Inhibitors Make Headway in HER2+ and Triple-Negative Breast Cancers

August 10th 2020

CDK4/6 inhibitors alone and/or in combination with HER2-directed therapies have been shown to elicit encouraging response rates and inhibit the growth of the cancer cells in HER2-positive breast cancer.

Multidisciplinary Collaboration Needed to Provide Cohesive Care in Advanced NSCLC

August 7th 2020

David R. Spigel, MD, discusses the Fostering Excellence in Care and Outcomes in Patients with Stage III and IV NSCLC initiative, analyzes the survey data, and next steps for the research.

Shaughnessy Speaks to the Rapidly Evolving Role of CAR T-cell Therapy in Hematologic Malignancies

August 5th 2020

Paul J. Shaughnessy, MD, discusses how CAR T-cell therapy is being utilized in hematologic malignancies, challenges faced with this modality, and ongoing research efforts being made to better leverage its use.

Dose-Adjusted Chemo Regimen Shows Efficacy in Burkitt Lymphoma, Regardless of Age or HIV Status

July 31st 2020

Findings from an ongoing, multicenter, phase 2 study identified an alternative treatment to dose intense chemotherapy through dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab for adults with untreated Burkitt lymphoma and diffuse large B-cell lymphoma.

Pembrolizumab Provides Long-Term Benefit in Melanoma, Regardless of BRAF+ Status or Prior Targeted Therapy

July 27th 2020

Pembrolizumab was found to prolong survival in patients with advanced melanoma, regardless of BRAF V600E/K mutation status or prior administration of a BRAF inhibitor with or without a MEK inhibitor.

Updated Data Confirm Long-Term Benefit With Tafasitamab/Lenalidomide in Relapsed/Refractory DLBCL

July 24th 2020

Tafasitamab plus lenalidomide followed by tafasitamab monotherapy was confirmed to induce durable responses and a clinically meaningful overall survival benefit in patients with relapsed/refractory diffuse large B-cell lymphoma.

ATHENA Trial of Maintenance Rucaparib/Nivolumab in Ovarian Cancer Completes Target Enrollment

July 23rd 2020

The pivotal phase 3 ATHENA trial, which will examine the safety and efficacy of rucaparib in combination with nivolumab as maintenance treatment following response to front-line platinum-based chemotherapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, has completed target enrollment.

USC73 Score Predictive of OS in Uterine Serous Carcinoma

July 23rd 2020

A 73-gene proliferative transcriptomic signature was found to better predict overall survival outcomes and potentially be used to personalize treatment in patients with uterine serous carcinoma.

Experts Highlight Promise of Trastuzumab Deruxtecan in Gastric/GEJ Cancers

July 21st 2020

Experts share their insight on the efficacy and safety of trastuzumab deruxtecan in the gastric cancer space.

Brufsky Spotlights Data With Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer

July 20th 2020

Adam M. Brufsky, MD, PhD, further discusses the utility of trastuzumab deruxtecan in HER2-positive breast cancer, ongoing research efforts examining the antibody–drug conjugate, and how he approaches sequencing in the paradigm.

Al-Sawaf Highlights the Benefit of Fixed-Duration Venetoclax/Obinutuzumab in CLL

July 17th 2020

Othman Al-Sawaf, MD, discusses the data from the CLL14 trial with obinutuzumab/venetoclax and the benefits of a fixed-dose treatment in select patients with chronic lymphocytic leukemia.

Han Highlights the Need for Personalized Treatment in HER2+ Early-Stage Breast Cancer

July 15th 2020

Heather Han, MD, discusses ongoing clinical trials within the field of HER2-positive breast cancer and the future of personalized treatment for this patient population.

Surgical Delays Linked With Higher Risk in Some Gastrointestinal Cancers

July 15th 2020

In light of the COVID-19 pandemic, many elective surgical procedures had been cancelled or rescheduled to maximize hospital capacity and prevent unnecessary exposure for patients, but surgical delays might lead to worse outcomes for certain patients with gastrointestinal cancers.

Pepinemab/Avelumab Combo Shows Early Tolerability and Antitumor Activity in Advanced NSCLC

July 15th 2020

The combination of pepinemab and avelumab was found to be well tolerated and demonstrated initial signals of antitumor activity in patients with advanced stage, non–small cell lung cancer.

Cytoreductive Nephrectomy Retains Role in mRCC in the Immune Checkpoint Inhibitor Era

July 13th 2020

Ziad Bakouny, MD, MSc, discusses the controversy behind the use of cytoreductive nephrectomy in metastatic renal cell carcinoma, factors to consider when selecting patients for this approach, and ongoing trials examining remaining questions in the field.

Krop Highlights Durable Activity With ADC in HER2+ Breast Cancer

July 12th 2020

Ian E. Krop, MD, PhD, discusses the pivotal data from the DESTINY-Breast01 trial, the need for longer-term follow-up with trastuzumab deruxtecan, and the proper management of interstitial lung disease.

AMG 510, AbGn-107 Prove to Be Effective, Tolerable in GI Cancers

July 10th 2020

Andrew L. Coveler, MD, discusses the early-phase data with AMG 510 and AbGn-107 in gastrointestinal malignancies.

Expert Highlights Unmet Need for Patients With Metastatic HER2+ Breast Cancer and Brain Metastases

July 6th 2020

Brian Czerniecki, MD, PhD, discusses how patients with metastatic HER2-positive breast cancer who later develop central nervous system metastases comprise a large population of all patients with breast cancer, and there continue to be an unmet need for this subgroup.

Optimal Sequence of Immunotherapy and Radiation Could Prolong Survival in Melanoma With Brain Metastases

July 6th 2020

A possible optimal sequence of radiation therapy and immune checkpoint inhibitors could help to prolong the survival of patients with melanoma who have brain metastases following surgical resection.